Business Growth Story

2021

• FDA submission for Bevacizumab.
• Approval in EU, Canada, Australia and many other highly regulated markets.
• Launch of CDMO strategic commercial activities.
2020

• New state-of-the-art mAbxience biomanufacturing facility opening in Argentina.
• Commercial presence via B2B partners in more than 100 markets.
• EMA approval for Bevacizumab.
• Manufacturing agreement for Astrazeneca Covid-19 vaccine.
2019

• Development of new assets for future pipeline, 2025.
• Partnered worldwide with Bevacizumab biosimilar.
2018

• Alliances with leading pharma companies in EU, USA, and Australia.
2017

• Expansion of global access of Rituximab & Bevacizumab.
• EMA GMP certification granted to Spanish facility.
2016

• First launch of Bevacizumab (Bevax®, Argentina).
• Global consortium established for the development of palivizumab biosimilar*.
• Global consortium with WHO for MB05.
2015

• Spain biomanufacturing and R&D center inauguration.
2014

• Acquisition of Genhelix, a Spanish biotech R&D center.
• First launch of Rituximab (Novex®, Argentina).
2012

• mAbxience Argentina biomanufacturing facility inauguration.
2010

• Company formation under Insud Pharma (Europe).
• Acquisition of PharmaADN, mAbxience´s Argentina R&D platform.